

Context-dependent selection as the keystone in the somatic evolution of cancer

Vibishan B.¹ and Milind G. Watve^{1,*}

¹Department of Biology, Indian Institute of Science Education and Research (IISER), Pune

*Corresponding author: milind@iiserpune.ac.in

February 5, 2019

Abstract

Somatic evolution of cancer involves a series of mutations, and attendant changes, in one or more clones of cells. Unlike a “bad luck” type model, the notion of clonal expansion adds competition-driven selection to the supposedly random process of somatic mutagenesis, with the implicit assumption that any mutation leading to partial loss of regulation of cell proliferation will give a selective advantage to the mutant. However, a number of experiments show that an intermediate pre-cancer mutant has only a conditional selective advantage; given that tissue microenvironmental conditions differ across individual organisms, this selective advantage to a mutant should be widely distributed over the population of organisms. We evaluate three models, namely “bad luck”, context-independent, and -dependent selection, in a comparative framework, on their ability to predict patterns in total incidence, age-specific incidence, and their ability to explain Petos paradox. Results show that context dependence is necessary and sufficient to explain observed epidemiological patterns, and that cancer incidence is largely selection-limited, as opposed to the mutation-centric, “bad luck” view. A wide range of physiological, genetic and behavioural factors influence the tissue micro-environment, and could therefore be the source of this context dependence in somatic evolution of cancer. The identification and targeting of these micro-environmental factors that influence the dynamics of selection offer new possibilities for cancer prevention.

Keywords: Somatic evolution, mutation accumulation, epidemiology, cancer etiology

Highlights

- We use a comparative modelling framework to assess the relative importance of random mutations as opposed to context-dependent selection.
- Somatic evolution of cancer is primarily selection-limited, rather than mutation-limited.
- This selective context could stem from several aspects of the tissue micro-environment, including growth factors, hormones, immune and ECM components.
- Understanding and controlling micro-environmental conditions offers novel avenues of cancer prevention and therapy.

1 Introduction

Mathematical models of somatic evolution in cancer have been in development for the past several decades, with a strong focus on mutational processes¹⁻⁴. Most prominently, Tomasetti et al. have argued that cancer risk is largely determined by random mutations^{5,6}. On the other hand, the question of somatic evolution in cancer parallels an old debate in the theory of evolution as to how the simple process of random mutations alone can lead to complex structures such as the eye which require the coordinated action of several genes, often perceived as the monkey-on-a-typewriter paradox⁷. The problem of cancer is qualitatively similar to this, but quantitatively even more difficult, since most cancers must evolve independently in each individual organism. All cancers are necessarily a combination of different types of genomic changes including point mutations, aneuploidy and other chromosomal aberrations, and the cancer phenotype has a large number of distinguishing characters, encapsulated by the notion of the “hallmarks” of cancer⁸⁻¹⁰. The wide range of characteristics that these hallmarks include make it astonishing that so many alterations in cell properties come together in cancers purely out of chance.

Selection on intermediate mutants was the logical solution provided for the monkey-on-a-typewriter paradox, and clonal expansion paralleled such a solution in cancer evolution. Every component mutation on the way to a cancerous phenotype causes the mutant clone to expand, and as the mutant population increases, the probability of a second component mutation increases proportionately¹¹. Implicit in this theory is the assumption that every component mutation has a selective advantage over the normal cell. Since most changes involved in carcinogenesis relate to evading growth regulatory mechanisms, it is considered logical that any mutation that allows for such evasion will have a natural selective advantage. However, evidence has been accumulating over the past few years that the fitness advantage of a mutant is largely dependent on the tissue micro-environment^{12,13}. Studies in mice¹⁴ and humans¹⁵ have demonstrated the effect of contingent factors, such as behavioural profiles and lifestyle parameters, on cancer progression. These findings provide clear indications that the selective forces which determine mutant clone fitness can vary considerably across individuals, leading to *context-dependent clonal expansion* of potentially oncogenic mutants. The role of such differential selective forces in somatic evolution has not been adequately addressed by cancer models so far.

In this paper, we compare three modelling approaches, two of which explicitly include selection at different levels: (1) random mutagenesis, or the “bad luck” hypothesis, (2) context-independent expansion of mutant clones within individuals, and (3) context-dependent selection acting across individuals. Genetic mutations are a fundamental aspect of multi-stage models of carcinogenesis. In our models however, we use the term mutation more broadly, to denote any change that is heritable within a given cell lineage, genetic or epigenetic.

Since well-curated data are available for human cancer incidence patterns through the SEER databases¹⁶, we develop models of these three processes, and compare their predictions with the epidemiological picture of cancer in the human population. A good working model of somatic evolution of cancer needs to explain the following epidemiological features:

1. Total and age-specific incidence: Total incidence of cancer across types lies below 30%, while age-specific and cumulative incidence patterns show more variations between cancer types¹⁶. Interestingly, recent analyses have shown for several cancers that the age-specific incidence rates decline late in life¹⁷, in contrast with general model predictions of a power law increase in incidence with age. Some theoretical explanations for this decline have been suggested¹⁸, but exact causes remain unclear. The late-life decline causes the cumulative incidence to saturate with age at a small percentage of the population size. No matter the lifespan, the proportion of cancer in the population can never reach 100%, which represents a finite limit that is not determined by time.
2. Incidence vs cell number: The relationship between cancer risk and cell number (as the lifetime number of cell divisions, *lscd*) has been kept in the spotlight by recent work by Tomasetti et al.^{5,6}. Although the linearity of the relationship between *lscd* and cancer risk is still under debate, available data can be used to comparatively test model predictions.
3. Incidence vs mutation rate: Empirical data on this relationship are less common, as mutation rates are difficult to measure reliably, although some efforts have been made¹⁹. However, a general notion exists that higher mutation rates increases cancer risk, and this remains to be tested rigorously, barring theoretical work dealing with the effect of mutagens on patterns in incidence data¹⁸.
4. Non-mutagenic carcinogens: There are several agents, including hormones and growth factors, that increase cancer risk without affecting the basal mutation rate²⁰. The activity of these agents, and their signature in epidemiological patterns, are both important in building a complete framework of explaining cancer etiology.
5. Peto’s paradox, and similar observations: This relates to the incidence-cell number relationship, as cancer risk is seen not to scale with body size or cell number across species²¹, but may correlate with the latter within a species²². A wide range of explanations have been offered for this observation²³, and in a modeling context, these explanations can come from the model itself (intrinsic), or involve extrinsic factors, such as evolved cancer defences, that are not part of the model framework.

2 The “bad luck” model

This hypothesis assumes that the required set of driver mutations accumulate in a cell by chance alone. This may happen over a period of time, or in a single large-scale event, like chromothripsis²⁴. Regardless of whether mutations accumulate sequentially or otherwise, the “bad luck” model does not assume selection of any kind on mutations over the course of somatic evolution.

Consider an organism with a population of n stem cells, each with a mutation rate per cell generation per locus, p . The probability that at least one cell acquires one mutation at a given point of time can be given as $1 - (1 - p)^n$. If k such mutations are required for cancer onset, the probability of cancer according to the bad luck model can be given as below, based on an algebraic formulation²⁵:

$$p_{can} = 1 - (1 - p^k)^n \quad (1)$$

Given the probability of cancer per unit time, p_{can} from equation 1, the cumulative incidence of cancer for age, A , can be expressed as below:

$$p_A = 1 - (1 - p_{can})^A \quad (2)$$

From equation 1, it is clear that the probability of cancer has a threshold relationship with both n and p , such that incidence rises from near zero to 100% over a small range of p and n , as shown in Figure 1.

From equation 2, the relationship of p_{can} with age is a monotonically increasing function with a maximum at one. Figure 2 shows this relationship across the entire parameter range of n and p , for which this prediction holds. Cancer probability increases monotonically with age, and only saturates at 100% incidence, which stands in stark contrast to the observed late-life decline in age-specific rates. Given a finite lifespan, cancer incidence lies in a realistic range in a narrow range of p and n .

Including the cost of lethal/deleterious passenger mutations does not qualitatively alter the general prediction of thresholds with n , p and age, although the position of the threshold may change, as has been observed independently². Taken together, this formulation of the “bad luck” model predicts a sharp threshold relationship of cancer probability with both n and p , as opposed to the observed progressive increase^{5,6}. For values of n and p around this threshold, cancer probability increases rapidly with age but is inconsistent with late-life decline in cancer incidence.

3 Models with selection on mutants

For models that involve selection, we choose to explore the effects of context-independent clonal expansion and context-dependent selection through a simulation-based stochastic framework.

We use a linear process to model the sequential accumulation of mutations in a population of stem cells. We begin by considering the development of a generalized tissue compartment




Figure 1: Cancer probability, p_{can} vs cell number for the “bad luck” model; p_{can} remains near zero in part of the parameter range, and rises to one over a narrow region of the corresponding parameter. This probability is cumulative and therefore reflects total incidence in the population. For the “bad luck” model, the total incidence is rarely in the observed range of around 30%. The number of oncogenic mutations required for cancer onset (k) does not affect the existence of a threshold with n and p , but does affect where the threshold occurs in the parameter space; for $k = 10$, the threshold does not occur within the tested range of n and p . The legend shows values of p for each curve.




Figure 2: Cancer probability vs age, as given by equation 2, (a and b) over the range of n , and (c and d) over the range of p ; inset legends give the corresponding values of n and p . Cancer probability increases monotonically with age, saturating only at one in most cases. Where the probability does approach realistic values of total incidence, it still does not reflect the late-life decline in incidence rates observed epidemiologically. As in Figure 1, the number of oncogenic mutations required for cancer onset does not change the nature of the incidence-age relationship. For a and c, $k = 2$, and for b and d, $k = 5$.

in each organism starting from one stem cell, with mutation rate per cell generation per locus, p , growing logistically to a carrying capacity, n , following the discrete logistic equation below:

$$m_{i,t} = m_{i,t-1} + m_{i,t-1} * g_i * \left(\frac{n - \sum_{i=0}^k m_{i,t-1}}{n} \right) - m_{i,t-1} * d \quad (3)$$

Here, $m_{i,t}$ is the size of the i th mutant population at time, t , with $i = 0$ being the non-

mutant cell population, g_i is the corresponding logistic growth rate, d is the common death rate, and k is the threshold number of oncogenic mutations required for cancer onset. As the organism develops into an adult, net growth in the stem cell compartment saturates, but reaches a dynamic equilibrium between cell death and renewal. The stem cell population can be reduced, either by death of stem cells or differentiation, as reflected by the death rate in equation 3. Assuming a common death rate for all cell populations, the replacement of the lost cells by either mutants or non-mutants is a function of their growth rates. We simulate new mutation events stochastically; the probability of at least one cell mutating is given by $1 - (1 - p)^{m_{i,t}}$, and if this probability exceeds a random number between 0 and 1, a new $(i + 1)$ th mutant population is initiated. Each new oncogenic mutation could give a growth advantage over older cell populations, leading to successive cycles of clonal expansion in which the newer population gradually replaces older cells through competitive exclusion. We simulate this linear evolution process until k mutations have been accumulated, which is the assumed threshold for cancer onset. Death of the individual occurs either at cancer onset when the k th mutation occurs, or at the end of the natural lifespan of 100 years, whichever happens first. This simulation is repeated independently for a population of 10000 individuals, and the population-level cancer incidence is recorded, along with the age of onset.

3.1 Choice of parameter range

In order to standardize the discrete logistic simulation, we assume the time unit to be one day per logistic growth step. Most human organs complete development and maturation within the first 10-20 years of the lifespan, and the final carrying capacity achieved is the adult stem cell number, ranging between 10^6 and 10^{11} across different tissues (supplementary material from⁵). Given the final population size and the time taken to reach it, a simple calculation based on the logistic equation shows the required growth rate for a non-mutant stem cell to be in the range of 0.00383-0.0131. Starting from the non-mutant growth rate, g_0 , growth rates are assumed to increase linearly for each subsequent mutant population, with the slope given by $\Delta_g = \frac{g_k - g_0}{k}$. Ranges of n and p are retained as in the “bad luck” model.

3.2 The context-independent selection case

While the clonal expansion theory introduced the notion of selective advantages to oncogenic mutants, it makes the implicit assumption that identical mutations have the same selective advantage in every individual in which they occur; stated otherwise, individuals do not differ in their propensity for mutant clonal expansion. To capture this in the context-independent selection case, we use the same slope, Δ_g for all individuals in the simulation.

3.3 The context-dependent selection case

As argued earlier, it is becoming increasingly clear that the competitive outcomes of identical mutations can depend strongly on the micro-environmental context in which cell competition occurs. In order for selection on mutants to be context-dependent in our model, we randomize

the slope, Δ_g from a given normal distribution. Each individual begins with the same g_0 , but the progression of growth rates is randomized across individuals, such that individuals with large g_i would progress faster towards cancer onset, while those with small, or negative values of g_i would never progress to a cancerous state as the mutant gets selected against. This produces variation across organisms for cancer propensity.

3.4 Predictions from the selection models

As in Figure 3, under the assumption of context-independent selection, the incidence of cancer shows a strong threshold relationship with age, where up to a certain age, cancer is unlikely or rare, but increases rapidly to 100% within a relatively short span of time. This is indicated by the fact that the cumulative incidence reaches 100% within the individual lifespan, and the age-specific incidence falls to zero. As with the “bad luck” model, incidence has a threshold relationship with both n and p , as reflected in the maximum cumulative incidence, I_{max} (Figure 3d and h). The age at half-maximum incidence is a decreasing function of both n and p (Figure 3c and g). Moreover, saturation of incidence occurs only at 100%, which is identical to the “bad luck” model, despite the inherently stochastic implementation of mutation occurrence. Where the incidence of cancer is near the realistic range, for small values of p and n , the late-life decrease in incidence is still not reflected in the context-independent selection case. The prediction of 100% incidence is due to the fact that all organisms in the population share the same growth rate progression for mutants. No other parameter in the model inherently precludes the accumulation of all k oncogenic mutations in some individuals; giving a distribution to p reduces the sharpness of the incidence threshold with age, but saturation of incidence remains at 100% (Figure 4).

As opposed to the context-independent selection model, the context-dependent model produces a saturating trend in cumulative incidence that begins to saturate at a level much lower than 100% (Figure 5). This is an important feature of the context-dependent model, as it allows the model to generate more realistic patterns in age-specific cancer incidence. The saturation occurs because propensity for clonal expansion varies across individuals; cancer progression occurs very quickly in some individuals, and not at all in others. Of the three models analysed so far, only the context-dependent model captures a trend similar to the late-life decline observed in many cancers in humans, as the crude incidence curves in Figure 5a and e show. It is also important to note that cancer incidence increases progressively over several orders of magnitude of both n and p , as opposed to the thresholds observed in earlier models (Figure 5c and g).

4 Sensitivity of predictions

Randomizing k in the range, $[2, 10]$ ²⁶, the nature of the relationships did not change qualitatively, although k affected the age of cancer onset (Supplementary figures, S2.1-S2.4). As different types of cancers may have different k ²⁷, the effects of n and age on incidence trends could also change correspondingly. This is also relevant to the study of similar patterns that do not show up at the whole population level, but may become apparent if the population is stratified by the number of driver mutations, which in turn is known to vary across cancer




Figure 3: Incidence patterns from the context-independent selection model over the range of (a-d) n , and (e-h) p . From left to right in each row, the plots are of (a, e) age-specific crude incidence per 100,000 vs age, (b, f) cumulative incidence (% of simulated population) vs age, (c, g) age at which half the maximum incidence is reached vs n or p , and (d, h) the maximum cumulative incidence, I_{max} vs n or p . Incidence saturates only at 100%, both with time (b and f), and with n and p (d and h). Inset legends for the age curves are $\log(n)$ and $\log(p)$ in the top and bottom row respectively. For a-d, $p = 5.603 * 10^{-9}$, and for e-h, $n = 1.785 * 10^8$. Growth rates progress linearly in the general form, $g_i = 0.007 * (i + 1)$, where $i = 0, \dots, k$ and $k = 5$. Here, $\Delta_g = \frac{0.007*k}{k} = 0.007$.

types.

To test whether the assumption of a normal distribution for Δ_g is critical for the results, we reevaluated the predictions of the context-dependent selection model for a Gumbel- and uniformly-distributed Δ_g progression. We find that the shape of the distribution does not affect the saturation of cumulative incidence, or the late-life decline in age-specific incidence predicted by the model, although the shape of the age curve changes (Supplementary material, S1 Figures).

Both our selection models assume a linear somatic evolution process by which mutations accumulate, by which the tissue has only one evolving lineage of cells at a time. Alternative modalities have been suggested for tumour evolution, like branched, neutral and punctuated modes²⁸, and some modelling effort has gone into studying branched processes in somatic evolution²⁹. We do not explicitly model branched somatic evolution in our framework as it is computation-intensive, but our framework is, in principle, compatible with such analysis, given more efficient implementations. Qualitatively, we do not expect the linear evolution assumption to affect our primary conclusion that somatic evolution of cancer is largely selection-limited and not mutation-limited. In fact, a branched evolution process allows for a wider range of ecological interactions between sub-clonal populations, mutualistic or otherwise^{30,31}. Such interactions again lend into a selection-driven framework rather than a “bad luck”-driven one.

Somatic cell populations are potentially susceptible to mutational meltdown, and a large




Figure 4: Cumulative incidence (%) of simulated population) with randomized vs fixed p for the population in the context-independent selection case; giving a distribution to p does not reduce the saturation of incidence from 100%, but slows the transition to 100%. In the randomized case, p values were drawn from a uniform distribution with range $[3.775 \times 10^{-11}, 3.06 \times 10^{-7}]$ and mean, $\bar{p} = 4.17 \times 10^{-7}$, while for the fixed case, $p = 3.06 \times 10^{-7}$; for both, $n = 1.785 \times 10^8$ and $k = 5$.




Figure 5: Incidence patterns from the context-dependent selection model over the range of (a-d) n , and (e-h) p . From left to right in each row, the plots are of (a, e) age-specific crude incidence per 100000 vs age, (b, f) cumulative incidence (%) of simulated population) vs age, (c, g) age at which half the maximum incidence is reached vs $\log(n)$ or $\log(p)$, and (d, h) the maximum cumulative incidence, I_{max} vs n or p . As opposed to Figure 3, cumulative incidence saturates much below 100%, both with time (b and f), and with n (d), when g is randomized in the population. Note that randomization of p alone in the population does not reproduce these patterns (Figure 4). Inset legends for the age curves are $\log(n)$ and $\log(p)$ in the top and bottom row respectively. For a-d, $p = 5.603 \times 10^{-9}$; for c-h, $n = 1.785 \times 10^8$; and for all figures, $k = 5$. Insets for the incidence curves show $\log(n)$ and $\log(p)$ in the top and bottom rows respectively. Growth rates progress linearly from $g_0 = 0.007$ to $g_k = 0.007 * \mu$, where μ is normally-distributed random variable with $\bar{\mu} = 3$ and $\sigma = 5$. Here, $\Delta_g = \frac{0.007 * (\mu - 1)}{k}$.

number of somatic mutations are in fact known to be deleterious. Earlier analysis of the effect of passenger mutations has shown that accounting for them in somatic evolution de-

lays overall incidence of cancer in the population². However, from our context-independent selection case, we see that when total incidence in the population decreases, most cases of cancer are concentrated later in life, similar to the delay in incidence noted before². This pattern is not compatible with the observed late-life decline in incidence. We expect therefore that mutational meltdown due to deleterious passenger mutations is insufficient to explain saturation due to late-life decline in incidence.

5 Discussion

Table 1 compares the prediction profile of the three models discussed so far. On the whole, the better prediction profile of the context-dependent model stems from the distribution of Δ_g in the population, and this has interesting implications for the kind of causal factors that are important in explaining cancer etiology. One of these implications concern the mutation-centric thinking that represents the mainstream view in cancer biology. For instance, several growth factors and hormones are known to increase cancer risk, not the least of which is insulin, without increasing the basal mutation rate or the cell number. The action of such “non-mutagenic carcinogens” is not compatible with a mutation-centric approach to carcinogenesis. We propose instead that non-mutagenic carcinogens could act by altering Δ_g . Late-life incidence in the model comes from a slow growth rate progression across mutations, and our analysis suggests that differential progression of mutant growth rates across individuals is sufficient to produce a gradual decline in late-life cancer incidence. This decline is qualitatively different from the age curves of the context-independent model, where incidence drops abruptly over a narrow age range. In the context-dependent selection model, the gradual late-life decline in incidence stems from the left-hand tail of the Δ_g distribution, where some individuals have zero or negative progression of mutations. It becomes important therefore, to consider the local or evolutionary factors underlying such a temporal pattern of mutation accumulation which could potentially alter features of the Δ_g distribution. Likewise, the distribution of growth rate progression over the population could also form part of the explanation for saturation of total cancer incidence in the population across tissue types; the negative part of the Δ_g distribution precludes some part of the population from ever accumulating enough oncogenic mutations for cancer to occur. This line of thinking can also be extended to address Peto’s paradox. It is not a new argument that Peto’s paradox can be explained by invoking selection^{22,23,32}. The results from our model in fact reinforce the notion that somatic evolution of cancer is largely selection-limited, rather than mutation-limited, which explains why cancer risk does not increase in proportion with cell number and/or body size²¹. Moreover, our analysis introduces the additional dimension of population-level variation in cancer propensity as part of the explanation of Peto’s paradox.

This variation in selection could be attributed to the micro-environment in the tumour or pre-cancerous niche, and includes all the factors that determine the selective advantage of oncogenic or pre-cancerous mutants. Cellular interactions with the extra-cellular matrix (ECM) are known to be important in tissue homeostasis³³ and the growth of cancer populations¹³. The tissue micro-environment is also a key player in the association between obesity and cancer risk, where obese ECM differs from normal ECM both biophysically³⁴ and functionally³⁵. The immune system also acts as an important mediator in cancer-related

Table 1: **Comparative explanatory power of the three models with respect to observed epidemiological trends**

Epidemiological observation	“Bad luck”	Context-independent selection	Context-dependent selection
Total incidence across cancer types does not exceed 30%	Saturation at 100% only	Saturation at 100% only	Saturation < 100% possible
Age-specific incidence decreases in old age for several cancers	No late-life decline	No late-life decline	Late-life decline predicted
Incidence vs n	Sharp threshold saturating at 100%	Sharp threshold saturating at 100%	Progressive increase over several orders of magnitude
The phenomenon of non-mutagenic carcinogens	No explanation offered	No explanation offered	Act through Δ_g distribution
Peto’s paradox-cancer risk saturates with n	Evolved cancer defences	Evolved cancer defences	Cancer incidence not mutation-limited

processes; a wide range of immune cells including fibroblasts and lymphocytes are known to aid cancer progression under modified contexts¹², and cancer is increasingly seen as an overactive or abnormal wound healing process⁹. *In vitro*, the IGF-II concentration in culture media is found to markedly alter the selective advantage of an IFG-II over-expressing mutant in cell competition³⁶. Pre-cancerous cell lines across cancer stages also show different growth properties depending on growth factor concentration in the culture medium³⁷. Similarly, levels of estrogen and progesterone are known play important roles in regulating mammary cell proliferation³⁸, secretion of ECM factors and tumour-stroma interactions³⁹, and growth factor production⁴⁰. More recently, experiments have been reported in which behaviourally-enriched environments or physical exercise seemed to show cancer-suppressive effects^{14,15} that correlate with levels of particular growth factors, while studies in mice have also shown substantial variation in tumour sizes induced by identical genetic clones across individuals⁴¹. These observations together suggest that context-dependent factors from the microenvironment, be they biophysical, ECM-derived, GF-derived or immunological, could play a limiting role in cancer progression. An alternative research therefore focus emerges, centered on these microenvironmental factors that drive context-dependent cancer progression, whose identification would lead to novel preventive measures, along with potential implications for therapy.

A composite view of cancer etiology requires not only the incorporation of these, and

other complexities in models, but also the comparative testing framework that continues to be rare in cancer literature, barring a few efforts¹⁸. The value of such a framework is immense, as it allows for falsification of factors that make predictions contrary to observed data; this falsification is frequently more robust and informative than an indirect confirmation of potential causal factors. With our analysis, we hope to bring this framework back into the mainstream at a time when the availability of large-scale data spanning levels of biological organization is better than ever before, from the population to the various cellular “-omes”. A comparative framework could prove more powerful now, in the context of robust data and computational techniques, and should therefore become a major focus for the cancer modeling effort.

Acknowledgements

The authors acknowledge critical input faculty members at the Department of Biology, IISER Pune. We thank Ketaki Bhagwat, Dr. Ruchika Kaul-Ghanekar, Prerna Raina, Dr. Anil Gore, and Dr. Sharmila Bhapat for useful discussions.

References

1. Armitage, P. & Doll, R. The Age Distribution of Cancer and a Multi-Stage Theory of Carcinogenesis. *British journal of cancer* **8**, 1–12. ISSN: 0007-0920 (Mar. 1954).
2. McFarland, C. D., Korolev, K. S., Kryukov, G. V., Sunyaev, S. R. & Mirny, L. A. Impact of deleterious passenger mutations on cancer progression. *Proceedings of the National Academy of Sciences* **110**, 2910–2915. ISSN: 0027-8424 (2013).
3. Blokzijl, F. *et al.* Tissue-specific mutation accumulation in human adult stem cells during life. *Nature* **538**, 260–264. ISSN: 14764687 (Oct. 2016).
4. Mina, M. *et al.* Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies. *Cancer Cell* **32**, 155–168.e6. ISSN: 15356108 (Aug. 2017).
5. Tomasetti, C. & Vogelstein, B. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. *Science* **347**, 78–81. ISSN: 0036-8075 (2015).
6. Tomasetti, C., Li, L. & Vogelstein, B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. *Science* **355**, 1330–1334. ISSN: 0036-8075 (Mar. 2017).
7. Dawkins, R. *The blind watchmaker : why the evidence of evolution reveals a universe without design* xvii, 358. ISBN: 0393315703. <http://books.wwnorton.com/books/The-Blind-Watchmaker/> (W. W. Norton & Company, 1996).
8. Hanahan, D. & Weinberg, R. The hallmarks of cancer. *Cell* **100**, 57–70. ISSN: 0092-8674 (2000).
9. Schäfer, M. & Werner, S. Cancer as an overhealing wound: An old hypothesis revisited. *Nature Reviews Molecular Cell Biology* **9**, 628–638. ISSN: 14710072 (2008).
10. Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. *Cell* **144**, 646–674. ISSN: 00928674 (2011).

11. Nowell, P. The clonal evolution of tumor cell populations. *Science* **194**, 23–28. ISSN: 0036-8075 (Oct. 1976).
12. Hanahan, D. & Coussens, L. M. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment. *Cancer Cell* **21**, 309–322. ISSN: 15356108 (2012).
13. Pietras, K. & Östman, A. Hallmarks of cancer: Interactions with the tumor stroma. *Experimental Cell Research* **316**, 1324–1331. ISSN: 00144827 (2010).
14. Cao, L. *et al.* Environmental and Genetic Activation of a Brain-Adipocyte BDNF/Lep-
tin Axis Causes Cancer Remission and Inhibition. *Cell* **142**, 52–64. ISSN: 00928674
(July 2010).
15. Rundqvist, H. *et al.* Effect of Acute Exercise on Prostate Cancer Cell Growth. *PLoS*
ONE **8** (ed Lobaccaro, J.-M. A.) e67579. ISSN: 1932-6203 (2013).
16. American Cancer Society. Cancer Facts & Figures 2016. *Cancer Facts & Figures 2016*,
1–9. ISSN: 00908258 (2016).
17. Harding, C., Pompei, F. & Wilson, R. Peak and decline in cancer incidence, mortality,
and prevalence at old ages. *Cancer* **118**, 1371–1386. ISSN: 0008543X (Mar. 2012).
18. Frank, S. A. *Dynamics of Cancer. Incidence, Inheritance, and Evolution* 1–378. ISBN:
ISBN-13: 978-0-691-13366-9. doi:[10.1086/598317](https://doi.org/10.1086/598317). arXiv: [arXiv:1011.1669v3](https://arxiv.org/abs/1011.1669v3) (Prince-
ton University Press, 2007).
19. Hao, D., Wang, L. & Di, L.-j. Distinct mutation accumulation rates among tissues
determine the variation in cancer risk. *Nature Publishing Group*, 1–5 (2016).
20. Tennant, R. W. A perspective on nonmutagenic mechanisms in carcinogenesis. **101**,
231–236. ISSN: 00916765 (Oct. 1993).
21. Nagy, J. D., Victor, E. M. & Cropper, J. H. Why don’t all whales have cancer? A novel
hypothesis resolving Peto’s paradox. *Integrative and Comparative Biology* **47**, 317–328.
ISSN: 15407063 (May 2007).
22. Noble, R., Kaltz, O. & Hochberg, M. E. Peto’s paradox and human cancers. *Philo-
sophical Transactions of the Royal Society B: Biological Sciences* **370**, 20150104. ISSN:
0962-8436 (July 2015).
23. Tollis, M., Boddy, A. M. & Maley, C. C. Peto’s Paradox: How has evolution solved the
problem of cancer prevention? *BMC Biology* **15**, 60. ISSN: 17417007 (Dec. 2017).
24. Stephens, P. J. *et al.* Massive genomic rearrangement acquired in a single catastrophic
event during cancer development. *Cell* **144**, 27–40. ISSN: 00928674 (2011).
25. Calabrese, P. & Shibata, D. A simple algebraic cancer equation: calculating how cancers
may arise with normal mutation rates. *BMC Cancer* **10**, 3. ISSN: 1471-2407 (Dec. 2010).
26. Martincorena, I. *et al.* Universal Patterns of Selection in Cancer and Somatic Tissues.
Cell **171**, 1029–1041.e21. ISSN: 10974172 (2017).
27. Nunney, L. & Muir, B. Peto’s paradox and the hallmarks of cancer: Constructing an
evolutionary framework for understanding the incidence of cancer. *Philosophical Trans-
actions of the Royal Society B: Biological Sciences* **370**, 20150161. ISSN: 14712970 (July
2015).

28. Davis, A., Gao, R. & Navin, N. Tumor evolution: Linear, branching, neutral or punctuated? *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer* **1867**, 151–161. ISSN: 0304419X (Apr. 2017).
29. Chowell, D. *et al.* Modeling the subclonal evolution of cancer cell populations. *Cancer Research* **78**, 830–839. ISSN: 15387445 (Feb. 2018).
30. Aktipis, C. A. & Nesse, R. M. Evolutionary foundations for cancer biology. *Evolutionary Applications* **6**, 144–159. ISSN: 17524571 (Jan. 2013).
31. Kareva, I. What Can Ecology Teach Us About Cancer? *Translational Oncology* **4**, 266–270. ISSN: 19365233 (2011).
32. Caulin, A. F. & Maley, C. C. *Peto's Paradox: Evolution's prescription for cancer prevention* Apr. 2011. doi:[10.1016/j.tree.2011.01.002](https://doi.org/10.1016/j.tree.2011.01.002). arXiv: [NIHMS150003](https://arxiv.org/abs/NIHMS150003). <https://www.sciencedirect.com/science/article/pii/S0169534711000152?via%7B%5C%7D3Dihub>.
33. Hansen, R. & Bissell, M. J. Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones. *Endocrine Related Cancer* **7**, 95–113. ISSN: 1351-0088 (2000).
34. Druso, J. E. & Fischbach, C. Biophysical Properties of Extracellular Matrix: Linking Obesity and Cancer. *Trends in Cancer*. ISSN: 24058033. doi:[10.1016/j.trecan.2018.02.001](https://doi.org/10.1016/j.trecan.2018.02.001). <http://linkinghub.elsevier.com/retrieve/pii/S2405803318300360> (2018).
35. Iyengar, N. M., Gucalp, A., Dannenberg, A. J. & Hudis, C. A. Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. *Journal of Clinical Oncology* **34**, 4270–4276. ISSN: 0732-183X (2016).
36. Archetti, M., Ferraro, D. A. & Christofori, G. Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer. *Proc Natl Acad Sci U S A* **112**, 1–6. ISSN: 1091-6490 (2015).
37. Chan, M. T. *et al.* Effects of insulin on human pancreatic cancer progression modeled in vitro. *BMC Cancer* **14**, 814. ISSN: 1471-2407 (Dec. 2014).
38. Haslam, S. Z. & Woodward, T. L. Tumour-stromal interactions Reciprocal regulation of extracellular matrix proteins and ovarian steroid activity in the mammary gland. *Breast Cancer Research* **3**, 365. ISSN: 1465-542X (2001).
39. Woodward, T. L., Xie, J., Fendrick, J. L. & Haslam, S. Z. Proliferation of Mouse Mammary Epithelial Cells in Vitro: Interactions among Epidermal Growth Factor, Insulin-Like Growth Factor I, Ovarian Hormones, and Extracellular Matrix Proteins 1. *Endocrinology* **141**, 3578–3586. ISSN: 0013-7227 (2000).
40. Dickson, R. B. & Lippman, M. E. Estrogenic Regulation of Growth and Polypeptide Growth Factor Secretion in Human Breast Carcinoma. *Endocrine Reviews* **8**, 29–43. ISSN: 0163-769X (1987).
41. Rogers, Z. N. *et al.* A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. *Nature Methods* **14**, 737–742. ISSN: 15487105 (May 2017).